These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23772696)

  • 21. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A model for estimating ovarian cancer risk: application for preventive oophorectomy.
    Giannakeas V; Sopik V; Shestopaloff K; Iqbal J; Rosen B; Akbari M; Narod SA
    Gynecol Oncol; 2015 Nov; 139(2):242-7. PubMed ID: 26341709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal.
    Ghadirian P; Robidoux A; Nassif E; Martin G; Potvin C; Patocskai E; Younan R; Larouche N; Venne A; Zhang S; Royer R; Narod SA
    Clin Genet; 2014 Jan; 85(1):31-5. PubMed ID: 23621881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
    Fostira F; Tsitlaidou M; Papadimitriou C; Pertesi M; Timotheadou E; Stavropoulou AV; Glentis S; Bournakis E; Bobos M; Pectasides D; Papakostas P; Pentheroudakis G; Gogas H; Skarlos P; Samantas E; Bafaloukos D; Kosmidis PA; Koutras A; Yannoukakos D; Konstantopoulou I; Fountzilas G
    Breast Cancer Res Treat; 2012 Jul; 134(1):353-62. PubMed ID: 22434525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Genetic test and prophylactic treatment in breast cancer families].
    Miyoshi Y; Noguchi S
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
    Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
    Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
    Segev Y; Iqbal J; Lubinski J; Gronwald J; Lynch HT; Moller P; Ghadirian P; Rosen B; Tung N; Kim-Sing C; Foulkes WD; Neuhausen SL; Senter L; Singer CF; Karlan B; Ping S; Narod SA;
    Gynecol Oncol; 2013 Jul; 130(1):127-31. PubMed ID: 23562522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A survey of preventive measures among BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
    Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
    EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
    Laki F; Kirova YM; This P; Plancher C; Asselain B; Sastre X; Stoppa-Lyonnet D; Salmon R;
    Cancer; 2007 May; 109(9):1784-90. PubMed ID: 17351952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic approaches for women predisposed to breast cancer.
    Nathanson KL; Domchek SM
    Annu Rev Med; 2011; 62():295-306. PubMed ID: 21034216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.